Cardiac Myosin Inhibitor Gets FDA's Blessing for Obstructive HCM

(MedPage Today) -- The FDA approved mavacamten (Camzyos) for the treatment of obstructive hypertrophic cardiomyopathy (HCM) in people with New York Heart Association class II-III symptoms -- but on the condition it would only be available through...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news